News | September 04, 2024
Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
ZenBio is a highly regarded science-focused company specializing in biospecimens and related services with scientific expertise
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Subscribe To Our Newsletter & Stay Updated
